MONTGOMERY, Texas--(BUSINESS WIRE)--Endovasc, Inc. - (OTCBB: EVSC), a Business Development Company focused on acquiring and investing in companies engaged in the development of innovative cardiovascular and metabolic drugs as well as nutraceutical supplements, confirmed that it has received a letter from the Securities and Exchange Commission (SEC), and intends to respond promptly to the queries raised by the SEC.
